Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective study of anti-CTLA-4 and/or anti-PD-1 therapy in patient with metastatic melanoma with and without detectable NRAS mutation

Trial Profile

Retrospective study of anti-CTLA-4 and/or anti-PD-1 therapy in patient with metastatic melanoma with and without detectable NRAS mutation

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 New trial record
    • 26 May 2018 Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top